Teva Pharmaceutical Industries Limited

Tel Aviv Stock Exchange TEVA.TA

Teva Pharmaceutical Industries Limited Gross Profit Margin for the year ending December 31, 2023: 48.25%

Teva Pharmaceutical Industries Limited Gross Profit Margin is 48.25% for the year ending December 31, 2023, a 3.28% change year over year. Gross Profit Ratio is the ratio of gross profit to net sales, indicating the percentage of revenue that exceeds the cost of goods sold and reflects the efficiency of a company in managing its production or procurement and sales.
  • Teva Pharmaceutical Industries Limited Gross Profit Margin for the year ending December 31, 2022 was 46.72%, a -2.31% change year over year.
  • Teva Pharmaceutical Industries Limited Gross Profit Margin for the year ending December 31, 2021 was 47.83%, a 3.13% change year over year.
  • Teva Pharmaceutical Industries Limited Gross Profit Margin for the year ending December 31, 2020 was 46.37%, a 3.92% change year over year.
  • Teva Pharmaceutical Industries Limited Gross Profit Margin for the year ending December 31, 2019 was 44.63%, a 1.42% change year over year.
Key data
Date Gross Profit Margin Operating Income Margin EBT Margin Net Income Margin
Market news
Loading...
Tel Aviv Stock Exchange: TEVA.TA

Teva Pharmaceutical Industries Limited

CEO Mr. Richard D. Francis
IPO Date Aug. 12, 2002
Location Israel
Headquarters 124 Dvora Hanevi’a Street
Employees 37,000
Sector Health Care
Industries
Description

Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, and internationally. The company offers sterile products, hormones, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams. It also develops, manufactures, and sells active pharmaceutical ingredients. In addition, it focuses on the central nervous system, pain, respiratory, and oncology areas. Its products in the central nervous system include Copaxone for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine; and AUSTEDO for the treatment of tardive dyskinesia and chorea associated with Huntington disease. The company's products in the respiratory market comprise ProAir, QVAR, ProAir Digihaler, AirDuo Digihaler, and ArmonAir Digihaler, BRALTUS, CINQAIR/CINQAERO, DuoResp Spiromax, and AirDuo RespiClick/ArmonAir RespiClick for the treatment of asthma and chronic obstructive pulmonary disease. Its products in the oncology market include Bendeka, Treanda, Granix, Trisenox, Lonquex, and Tevagrastim/Ratiograstim. Teva Pharmaceutical Industries Limited has a collaboration MedinCell for the development and commercialization of multiple long-acting injectable products, a risperidone suspension for the treatment of patients with schizophrenia. The company was founded in 1901 and is headquartered in Tel Aviv-Yafo, Israel.

Similar companies

LUMI.TA

Bank Leumi Le-Israel B.M.

USD 12.30

0.72%

ELAL.TA

El Al Israel Airlines Ltd.

USD 2.56

-3.58%

BEZQ.TA

Bezeq The Israel Telecommunication Corp. Ltd

USD 1.56

3.32%

TSEM.TA

Tower Semiconductor Ltd.

USD 50.62

-2.66%

ESLT.TA

Elbit Systems Ltd.

USD 292.23

-0.16%

StockViz Staff

January 15, 2025

Any question? Send us an email